

**Amendments to the Specification:**

Please insert the following new heading and paragraph after the title on page 1.

**CROSS REFERENCE TO PRIOR APPLICATIONS**

This application is a continuation application of pending U.S. application serial number 10/630,655, filed July 31, 2003 (of which the entire disclosure of the pending, prior application is hereby incorporated by reference), which is a continuation application of pending U.S. application serial number 10/198,364, filed July 19, 2002, now U.S. Patent No. 6,630,129, which is a continuation of U.S. application serial number 09/659,492, filed September 11, 2000, which is now U.S. Patent No. 6,479,035.

Please replace the first full paragraph on page 19 with the following amended paragraph.

A study was performed using an Andersen Cascade Impactor to compare the properties of formulations containing different solubilising agents. An actuator of dimensions 0.22mm x0.65 mm was used for the study. The results of the analysis of the formulations of Example 9 Formulations 9a, 9b, 9c and 9d and a comparison with the formulations of Example 3 Formulation 3c and Example 4 Formulation 4c are shown in Table 6 and Figure 15. The ethanol with glycerol profile clearly appears the most attractive since it demonstrates the highest FPM content in view of the high dosing in stages 4 and [[4]] 5 relative to the other profiles. Nevertheless the methylal profiles also looked of significant interest in view of the very low throat deposition. The addition of 1% glycerol shifted the methylal profile to lower stages only to a small extent, perhaps in view of its greater volatility than ethanol. A higher percentage of glycerol would be expected to increase the magnitude of the shift.